Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Sichuan Provincial People's Hospital
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
The TP regimen, as defined in clinical research by Sichuan Provincial People's Hospital, is a neoadjuvant chemotherapy combination for HER2-negative early breast cancer. It consists of nab-paclitaxel (an albumin-bound nanoparticle formulation of paclitaxel) and a platinum-based agent, specifically either cisplatin or carboplatin. Nab-paclitaxel functions as a microtubule stabilizer, preventing the depolymerization of tubulin and thereby arresting the cell cycle in the G2/M phase. The platinum components, cisplatin and carboplatin, act as DNA alkylating-like agents that form intra-strand and inter-strand cross-links, leading to DNA damage and apoptosis. This regimen is particularly being investigated for its efficacy in patients with homologous recombination deficiency (HRD) and triple-negative breast cancer (TNBC) subtypes, often compared against standard anthracycline/taxane (AT) regimens.
- Other names
- TP regimennab-paclitaxel plus platinum
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on nab-paclitaxel + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + cisplatin + carboplatin.